Filippos Katsaitis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Filippos Katsaitis has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Ioannis Sotiropoulos
Life and Health Sciences Research Institute (ICVS), University of Minho
2 shared publications - Adamantia Kouvela
Department of Biochemistry, School of Medicine, University of Patras, 26504 Patras, Greece
1 shared publication Aggeliki Dimopoulou
Laboratory of Developmental Biology, Department of Biology, University of Patras, Patras, Greece
1 shared publicationAmber R. Philp
Laboratory of Stem Cells and Neuroregeneration, Institute of Anatomy, Histology and Pathology, Faculty of Medicine, Universidad Austral de Chile, Valdivia, Chile & Center for Interdisciplinary Studies on the Nervous System (CISNe), Universidad Austral de Chile, Valdivia, Chile
1 shared publicationAntonios Emvalomatis
1 shared publication- Beatriz Barros-Santos
Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, 4710-057 Braga, Portugal
1 shared publication
Latest Publications
- Open Access
- 24 July 2026
- Published by Elsevier in Neuroscience Applied
- Vol. 5
Mental health and gut-brain crosstalk: implications for depression and Alzheimer's disease
- 24 July 2026
- Published by Elsevier in Neuroscience Applied
- Vol. 5
Open AccessMental health and gut-brain crosstalk: implications for depression and Alzheimer's disease
- Open Access
- 24 November 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1640
Platelets regulate neural and oligodendroglial progenitors when infiltrating the brain parenchyma
The mammalian, including the human, postnatal brain harbors distinct neurogenic and oligodendrogenic progenitor populations, whose activity during homeostasis and degeneration is closely related to blood vessels. Here, we investigated the regulatory role of platelets, that are easily and unlimitedly accessible and can modulate tissue regeneration. In co-cultures, platelets created a pro-stemness environment for neural stem/progenitor cells (NSPCs) and enhanced the differentiation of oligodendrocyte progenitor cells. The effects were dependent on platelet numbers and the culture microenvironment, while the molecular signature of the NSPC response confirmed the role of Platelet-Derived Growth Factor and the upregulation of stemness-promoting genes. The same effects were exerted in vivo, but only when platelets were injected directly into the striatal parenchyma or were extravasated, in severely thrombocytopenic mice. In contrast, thrombocytopenia without platelet tissue-infiltration, in Nbeal2 knockout mice, did not affect the brain’s progenitors. Our results, demonstrate the potential value of platelets in neuro-regenerative strategies.
- 24 November 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1640
Open AccessPlatelets regulate neural and oligodendroglial progenitors when infiltrating the brain parenchyma
The mammalian, including the human, postnatal brain harbors distinct neurogenic and oligodendrogenic progenitor populations, whose activity during homeostasis and degeneration is closely related to blood vessels. Here, we investigated the regulatory role of platelets, that are easily and unlimitedly accessible and can modulate tissue regeneration. In co-cultures, platelets created a pro-stemness environment for neural stem/progenitor cells (NSPCs) and enhanced the differentiation of oligodendrocyte progenitor cells. The effects were dependent on platelet numbers and the culture microenvironment, while the molecular signature of the NSPC response confirmed the role of Platelet-Derived Growth Factor and the upregulation of stemness-promoting genes. The same effects were exerted in vivo, but only when platelets were injected directly into the striatal parenchyma or were extravasated, in severely thrombocytopenic mice. In contrast, thrombocytopenia without platelet tissue-infiltration, in Nbeal2 knockout mice, did not affect the brain’s progenitors. Our results, demonstrate the potential value of platelets in neuro-regenerative strategies.
- Open Access
- 7 November 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (45) , eady9811
NAD + reverses Alzheimer’s neurological deficits via regulating differential alternative RNA splicing of EVA1C
Dysfunctional alternative splicing events (ASEs) in RNA are markers of aging and Alzheimer’s disease (AD). As a key neuronal resilience metabolite, the oxidized nicotinamide adenine dinucleotide (NAD + ) slows down AD progression in preclinical studies with several clinical trials ongoing. However, the underlying molecular mechanisms around how NAD + enhances neuronal resilience, especially whether it has any effect on ASEs, have remained elusive. This study shows that NAD + augmentation corrects the ASEs of many genes via a key protein, EVA1C (epithelial V-like antigen 1 homolog C), which is involved in neuronal development and activities. EVA1C is reduced in the hippocampus in patients with AD compared to cognitively normal ones. NAD + -induced memory retention is partially dependent on EVA1C, as adeno-associated virus–based Eva1c knockdown in the hippocampal CA1 region annuls NAD + -induced memory improvement in pathological Tau–bearing mice. We propose that NAD + reduces AD pathologies, at least partially, via amplification of the NAD + - EVA1C splicing axis, pointing to a potential splice-switching therapy for AD.
- 7 November 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (45) , eady9811
Open AccessNAD + reverses Alzheimer’s neurological deficits via regulating differential alternative RNA splicing of EVA1C
Dysfunctional alternative splicing events (ASEs) in RNA are markers of aging and Alzheimer’s disease (AD). As a key neuronal resilience metabolite, the oxidized nicotinamide adenine dinucleotide (NAD + ) slows down AD progression in preclinical studies with several clinical trials ongoing. However, the underlying molecular mechanisms around how NAD + enhances neuronal resilience, especially whether it has any effect on ASEs, have remained elusive. This study shows that NAD + augmentation corrects the ASEs of many genes via a key protein, EVA1C (epithelial V-like antigen 1 homolog C), which is involved in neuronal development and activities. EVA1C is reduced in the hippocampus in patients with AD compared to cognitively normal ones. NAD + -induced memory retention is partially dependent on EVA1C, as adeno-associated virus–based Eva1c knockdown in the hippocampal CA1 region annuls NAD + -induced memory improvement in pathological Tau–bearing mice. We propose that NAD + reduces AD pathologies, at least partially, via amplification of the NAD + - EVA1C splicing axis, pointing to a potential splice-switching therapy for AD.